Hsbc Holdings PLC Sells 53,897 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Hsbc Holdings PLC decreased its stake in shares of United Therapeutics Co. (NASDAQ:UTHR) by 46.2% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 62,861 shares of the biotechnology company’s stock after selling 53,897 shares during the period. Hsbc Holdings PLC owned 0.14% of United Therapeutics worth $20,033,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also bought and sold shares of the company. Renaissance Technologies LLC boosted its holdings in shares of United Therapeutics by 1.1% during the second quarter. Renaissance Technologies LLC now owns 2,174,692 shares of the biotechnology company’s stock worth $692,748,000 after acquiring an additional 22,978 shares during the period. LSV Asset Management boosted its stake in United Therapeutics by 82.5% in the 2nd quarter. LSV Asset Management now owns 966,370 shares of the biotechnology company’s stock valued at $307,837,000 after purchasing an additional 436,851 shares during the period. Dimensional Fund Advisors LP grew its holdings in United Therapeutics by 4.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 585,969 shares of the biotechnology company’s stock valued at $186,656,000 after buying an additional 22,683 shares in the last quarter. Norges Bank bought a new position in United Therapeutics during the 4th quarter worth $100,519,000. Finally, Swedbank AB acquired a new stake in shares of United Therapeutics during the first quarter worth $97,316,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Insider Activity

In related news, CEO Martine A. Rothblatt sold 3,600 shares of the business’s stock in a transaction on Monday, June 24th. The stock was sold at an average price of $315.97, for a total transaction of $1,137,492.00. Following the sale, the chief executive officer now owns 130 shares in the company, valued at approximately $41,076.10. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, CFO James Edgemond sold 7,802 shares of the business’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $345.41, for a total value of $2,694,888.82. Following the sale, the chief financial officer now owns 3,210 shares of the company’s stock, valued at $1,108,766.10. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Martine A. Rothblatt sold 3,600 shares of the firm’s stock in a transaction on Monday, June 24th. The stock was sold at an average price of $315.97, for a total value of $1,137,492.00. Following the transaction, the chief executive officer now directly owns 130 shares of the company’s stock, valued at $41,076.10. The disclosure for this sale can be found here. In the last ninety days, insiders sold 110,922 shares of company stock worth $36,541,398. Insiders own 12.50% of the company’s stock.

United Therapeutics Stock Up 0.5 %

Shares of NASDAQ UTHR opened at $353.00 on Friday. The company has a market cap of $15.66 billion, a price-to-earnings ratio of 16.69, a PEG ratio of 1.25 and a beta of 0.57. The company has a current ratio of 4.35, a quick ratio of 4.18 and a debt-to-equity ratio of 0.02. United Therapeutics Co. has a 12 month low of $208.62 and a 12 month high of $366.08. The stock has a 50-day moving average price of $339.19 and a two-hundred day moving average price of $291.68.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, July 31st. The biotechnology company reported $5.85 EPS for the quarter, missing the consensus estimate of $6.33 by ($0.48). United Therapeutics had a net margin of 40.87% and a return on equity of 18.82%. The company had revenue of $714.90 million during the quarter, compared to the consensus estimate of $691.87 million. During the same period in the previous year, the company earned $5.24 EPS. United Therapeutics’s revenue for the quarter was up 19.8% on a year-over-year basis. As a group, analysts forecast that United Therapeutics Co. will post 24.86 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms recently commented on UTHR. LADENBURG THALM/SH SH lowered shares of United Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 1st. StockNews.com downgraded shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Friday, August 2nd. TD Cowen boosted their price target on United Therapeutics from $270.00 to $350.00 and gave the company a “buy” rating in a research note on Thursday, July 11th. HC Wainwright restated a “buy” rating and set a $400.00 price objective on shares of United Therapeutics in a research note on Thursday, August 1st. Finally, Oppenheimer increased their target price on United Therapeutics from $400.00 to $575.00 and gave the stock an “outperform” rating in a report on Wednesday, August 28th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $350.36.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.